ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/HIF2a
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/HIF2a
4
trial(s) found.
NCT05536141
Advanced
Phase 1
Recruiting
A Phase 1, Open-label, Dose Escalation and Dose Expansion Study, to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of AB521 Monotherapy and Combination Therapies in Participants With Clear Cell Renal Cell Carcinoma and Other Solid Tumors (
ARC-20
)
HIF2a inhibitor
Clear cell renal cell carcinoma
SA
5037 - Glandore - Ashford Cancer Centre
NCT04924075
Advanced
Phase 2
Recruiting
A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, Formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With HIF-2α Related Genetic Alterations (
6482-015
)
HIF2a inhibitor
Gastrointestinal stromal tumour
Pancreatic neuroendocrine tumour
Paraganglioma
Phaeochromocytoma
Solid tumour
NSW
2031 - Randwick - Prince of Wales Hospital
VIC
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
NCT04524871
Advanced
Phase 1 / Phase 2
Recruiting
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (
Morpheus-Liver
)
ADG126
Atezolizumab
Bevacizumab
HIF2a inhibitor
NKT2152
PPAR-alpha inhibitor
TPST-1120
Tiragolumab
Tobemstomig
Tocilizumab
anti-CTLA4 monoclonal antibody
anti-IL-6 monoclonal antibody
anti-PD-L1 monoclonal antibody
anti-TIGIT monoclonal antibody
anti-VEGF monoclonal antibody
bispecific PD-1/LAG3 antibody
cancer therapy
cancer therapy,CTLA4-targeting
cancer therapy,HIF2a-targeting
cancer therapy,IL-6-targeting
cancer therapy,LAG3-targeting
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,PPAR-alpha-targeting
cancer therapy,TIGIT-targeting
cancer therapy,VEGF-targeting
immune checkpoint blockade
immune checkpoint blockade,CTLA4-targeting
immune checkpoint blockade,LAG3-targeting
immune checkpoint blockade,PD-1-targeting
immune checkpoint blockade,PD-L1-targeting
immune checkpoint blockade,TIGIT-targeting
immuno-oncology therapy,CTLA4-targeting
immuno-oncology therapy,IL-6-targeting
immuno-oncology therapy,LAG3-targeting
immuno-oncology therapy,PD-1-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,TIGIT-targeting
immuno-oncology therapy,VEGF-targeting
+ HIF2a inhibitor
Hepatocellular carcinoma
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT02861573
Advanced
Phase 1 / Phase 2
Recruiting
Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (
KEYNOTE-365
)
anti-PD-1 monoclonal antibody
+ HIF2a inhibitor
Castrate-resistant prostate cancer
NSW
2109 - North Ryde - Macquarie University Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (4)
Recruitment Country and State
NSW (2)
NZ (2)
SA (1)
VIC (1)
Phase
Phase 1 (1)
Phase 1 / Phase 2 (2)
Phase 2 (1)
Trial Type
Advanced (4)
Cancer Therapy Class
HIF2a
100%
PD-1
75%
PD-1/PD-L1
75%
TIGIT
50%
VEGF
50%
AXL
25%
KIT
25%
MET
25%
RET
25%
ROS1
25%
VEGFR
25%
VEGFR2
25%
CTLA4
25%
IL-6
25%
LAG3
25%
PD-L1
25%
PPAR-alpha
25%
AR
25%
CYP17A1
25%
PARP
25%
androgen axis
25%
Facility
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (2)
5037 - Glandore - Ashford Cancer Centre (1)
2031 - Randwick - Prince of Wales Hospital (1)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (1)
2109 - North Ryde - Macquarie University Hospital (1)
Cancer Type
Cancer
Solid tumour
Urogenital cancer
Gastrointestinal cancer
Upper gastrointestinal cancer
Clear cell renal cell carcinoma
Kidney cancer
Adrenal cancer
Endocrine gland cancer
Gastro-entero-pancreatic neuroendocrine tumour
Gastrointestinal stromal tumour
Neuroendocrine tumour
Pancreatic cancer
Pancreatic neuroendocrine tumour
Pancreatobiliary cancer
Paraganglioma
Phaeochromocytoma
Hepatobiliary cancer
Hepatocellular carcinoma
Castrate-resistant prostate cancer
Male genital cancers
Prostate adenocarcinoma
Prostate cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy